England Okays Funding For Revestive, Jyseleca & Fintepla
England’s health technology appraisal body NICE has recommended Galapagos’ Jyseleca for ulcerative colitis, Takeda’s Revestive for short bowel syndrome and Zogenix’s Fintepla for seizures associated with Dravet syndrome.
You may also be interested in...
Scotland has approved reimbursement for MSD’s Keytruda in combination with Eisai’s Lenvima for endometrial carcinoma. Meanwhile, a recommendation in England has been delayed.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
The Scottish health technology appraisal body, the SMC, has announced its recommendations on Sanofi’s Dupixent, Ipsen’s Cabometyx, Sobi’s Zynlonta and Novartis’ Cosentyx.